Low-dose growth hormone-releasing hormone tests: a dose-response study.

Spoudeas HA, Winrow AP, Hindmarsh PC, Brook CG

European journal of endocrinology1 Sept 1994Cited by 4 (Europe PMC)

PMID7921207DOI10.1530/eje.0.1310238PepBankPUB-07921207

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialActivity measurement
In 10 adult male volunteers, a 10 micrograms intravenous bolus of GHRH(1-29)NH2 produced a significantly higher peak GH than saline.
In plain wordsIn 10 healthy men, a 10 microgram injection of GHRH(1-29)NH2 raised peak growth hormone more than saline did.
Peptide
Sermorelin
Outcome
IncreasePeak GH response to 10 micrograms GHRH(1-29)NH2
Study
n = 10
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 micrograms · intravenousAs given in this study (human).
Measurements
Peak GH
24.03 mU/l
10 micrograms
Source sentences
Summary
Compared with saline, both 10- and 100-micrograms GHRH(1-29)NH2 doses (but not 1 microgram) resulted in significant peak GH responses (means and 95% confidence intervals: 24.03 (11.22-51.29) vs 26.09 (16.40-41.50) mU/l, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We have evaluated parameters of the serum growth hormone (GH) concentration response to saline and 1-, 10- and 100-micrograms intravenous bolus doses of amide analogue of GH-releasing hormone (GHRH (1-29)NH2) given in random order to 10 adult male volunteers of median body weight 68 (60-90)kg.
Report a problemFND-0792120701
02HumanRandomized controlled trialActivity measurement
In 10 adult male volunteers, a 100 micrograms intravenous bolus of GHRH(1-29)NH2 produced a significantly higher peak GH than saline.
In plain wordsIn 10 healthy men, a 100 microgram injection of GHRH(1-29)NH2 raised peak growth hormone more than saline did.
Peptide
Sermorelin
Outcome
IncreasePeak GH response to 100 micrograms GHRH(1-29)NH2
Study
n = 10
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms · intravenousAs given in this study (human).
Measurements
Peak GH
26.09 mU/l
100 micrograms
Source sentences
Summary
Compared with saline, both 10- and 100-micrograms GHRH(1-29)NH2 doses (but not 1 microgram) resulted in significant peak GH responses (means and 95% confidence intervals: 24.03 (11.22-51.29) vs 26.09 (16.40-41.50) mU/l, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We have evaluated parameters of the serum growth hormone (GH) concentration response to saline and 1-, 10- and 100-micrograms intravenous bolus doses of amide analogue of GH-releasing hormone (GHRH (1-29)NH2) given in random order to 10 adult male volunteers of median body weight 68 (60-90)kg.
Report a problemFND-0792120702
03HumanRandomized controlled trialActivity measurement
In 10 adult male volunteers, a 1 microgram intravenous bolus of GHRH(1-29)NH2 did not produce a significant peak GH response compared with saline.
In plain wordsIn 10 healthy men, a 1 microgram injection of GHRH(1-29)NH2 did not raise peak growth hormone significantly compared with saline.
Peptide
Sermorelin
Outcome
No significant changePeak GH response to 1 microgram GHRH(1-29)NH2
Study
n = 10
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram · intravenousAs given in this study (human).
Source sentences
Summary
Compared with saline, both 10- and 100-micrograms GHRH(1-29)NH2 doses (but not 1 microgram) resulted in significant peak GH responses (means and 95% confidence intervals: 24.03 (11.22-51.29) vs 26.09 (16.40-41.50) mU/l, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We have evaluated parameters of the serum growth hormone (GH) concentration response to saline and 1-, 10- and 100-micrograms intravenous bolus doses of amide analogue of GH-releasing hormone (GHRH (1-29)NH2) given in random order to 10 adult male volunteers of median body weight 68 (60-90)kg.
Report a problemFND-0792120703
04HumanRandomized controlled trialActivity measurement
In 10 adult male volunteers, the average rate of serum GH rise was similar after 10 and 100 micrograms of GHRH(1-29)NH2.
In plain wordsIn 10 healthy men, growth hormone rose at a similar speed after 10 and 100 microgram injections of GHRH(1-29)NH2.
Peptide
Sermorelin
Outcome
No significant changeRate of serum GH rise after 10 versus 100 micrograms
Study
n = 10
Comparator
10 micrograms versus 100 micrograms
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 and 100 micrograms · intravenousAs given in this study (human).
Measurements
Rate of serum GH rise
2.05 mU.l-1.min-1
10 micrograms
Rate of serum GH rise
1.52 mU.l-1.min-1
100 micrograms
Source sentences
Summary
Although the average rate of serum GH rise was similar after both 10 micrograms (2.05 (1.13-2.97) mU.l-1.min-1) and 100 micrograms of GHRH(1-29)NH2 (1.52 (0.69-2.35) mU.l-1.min-1; ANOVA F = 0.93, p = 0.35
1 context sentence(design, population, supporting numbers)
Summary · context
We have evaluated parameters of the serum growth hormone (GH) concentration response to saline and 1-, 10- and 100-micrograms intravenous bolus doses of amide analogue of GH-releasing hormone (GHRH (1-29)NH2) given in random order to 10 adult male volunteers of median body weight 68 (60-90)kg.
Report a problemFND-0792120704
05HumanRandomized controlled trialActivity measurement
In 10 adult male volunteers, serum GH declined more slowly after the peak with 100 micrograms of GHRH(1-29)NH2 than with 10 micrograms.
In plain wordsIn 10 healthy men, growth hormone fell more slowly after a 100 microgram injection of GHRH(1-29)NH2 than after a 10 microgram injection.
Peptide
Sermorelin
Outcome
DecreaseRate of serum GH decline after peak, 10 versus 100 micrograms
Study
n = 10
Comparator
10 micrograms versus 100 micrograms
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 and 100 micrograms · intravenousAs given in this study (human).
Measurements
Rate of serum GH decline
0.65 mU.l-1.min-1
10 micrograms
Rate of serum GH decline
0.37 mU.l-1.min-1
100 micrograms
Source sentences
Summary
the average rate of serum GH decline after peak GH was slower after the higher dose (10 micrograms vs 100 micrograms: 0.65 (0.40-0.90) vs 0.37 (0.23-0.50) mU.l-1.min-1; ANOVA F = 5.14, p = 0.04
1 context sentence(design, population, supporting numbers)
Summary · context
We have evaluated parameters of the serum growth hormone (GH) concentration response to saline and 1-, 10- and 100-micrograms intravenous bolus doses of amide analogue of GH-releasing hormone (GHRH (1-29)NH2) given in random order to 10 adult male volunteers of median body weight 68 (60-90)kg.
Report a problemFND-0792120705
06HumanRandomized controlled trialActivity measurement
In 10 adult male volunteers, increasing doses of GHRH(1-29)NH2 delayed the time to peak GH.
In plain wordsIn 10 healthy men, larger GHRH(1-29)NH2 doses made growth hormone reach its peak later.
Peptide
Sermorelin
Outcome
IncreaseTime to peak GH by dose
Study
n = 10
Comparator
1, 10 and 100 micrograms
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1, 10 and 100 micrograms · intravenousAs given in this study (human).
Measurements
Time to peak GH
7 min
1 microgram
Time to peak GH
15.8 min
10 micrograms
Time to peak GH
24.8 min
100 micrograms
Source sentences
Summary
Increasing GHRH(1-29)NH2 doses delayed the time to peak GH (1 microgram: 7.00 (3.50-10.52) min; 10 micrograms: 15.80 (13.62-17.98) min; 100 micrograms: 24.80 (18.40-31.12) min)
1 context sentence(design, population, supporting numbers)
Summary · context
We have evaluated parameters of the serum growth hormone (GH) concentration response to saline and 1-, 10- and 100-micrograms intravenous bolus doses of amide analogue of GH-releasing hormone (GHRH (1-29)NH2) given in random order to 10 adult male volunteers of median body weight 68 (60-90)kg.
Report a problemFND-0792120706
07HumanRandomized controlled trialActivity measurement
In 10 adult male volunteers, serum GH was still significantly elevated 2 hours after 100 micrograms of GHRH(1-29)NH2 compared with the other doses and saline.
In plain wordsIn 10 healthy men, growth hormone was still raised 2 hours after a 100 microgram GHRH(1-29)NH2 injection, compared with other doses and saline.
Peptide
Sermorelin
Outcome
IncreaseSerum GH 2 hours after 100 micrograms versus other doses
Study
n = 10
Comparator
Saline and 1 and 10 micrograms
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
100 micrograms · intravenousAs given in this study (human).
Measurements
Serum GH at 2 h
5.01 mU/l
100 micrograms
Serum GH at 2 h
0.98 mU/l
saline
Source sentences
Summary
serum GH levels were still elevated significantly 2 h after injection of 100 micrograms GHRH(1-29)NH2 compared with other doses (saline: 0.98 (0.48-2.04) mU/l; 1 microgram: 0.68 (0.48-0.93) mU/l; 10 micrograms: 1.07 (0.56-2.04) mU/l; 100 micrograms: 5.01 (2.34-10.86) mU/l; ANOVA F = 11.10, p < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
We have evaluated parameters of the serum growth hormone (GH) concentration response to saline and 1-, 10- and 100-micrograms intravenous bolus doses of amide analogue of GH-releasing hormone (GHRH (1-29)NH2) given in random order to 10 adult male volunteers of median body weight 68 (60-90)kg.
Report a problemFND-0792120707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.